AB Science Announces Recruitment of First Patient in Phase 3 Study of Masitinib in Severe Asthma
PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma.